Navigation Links
Innolife Pharma Inc. acquires rights to breakthrough in non-narcotic chronic pain treatment
Date:5/20/2008

Relief soon to be widely available for chronic pain sufferers.

MARKHAM, ON, May 20 /PRNewswire-FirstCall/ - Innolife Pharma, Inc. (Other OTC:INNP.PK - News) is pleased to announce that it has acquired North American licensing rights to the Natural Pain Relief Center non-narcotic proprietary breakthrough in the treatment of chronic pain.

Today, one in five Americans suffer with chronic pain (~ 60 million adults) spending approximately $120 Billion a year and the aging baby boomers have reported in surveys more aches and pains than any previous generation.

New Medical Finding with Brain Scans and Functional MRI's

Modern Brain Imaging has revealed that most chronic pain is the result of the brain's inability to turn off pain messages from the body. In chronic pain the brain simply is not producing and releasing enough natural pain killers (such as endorphins) to stop the person's suffering. These new medical findings show that chronic pain sufferers from headaches, migraines, fibromyalgia, back pain, sciatica, arthritis or a combination of all of them, are caused by a low level of Natural Pain Killer's (such as Endorphins and others) in the brain, as compared to people without chronic pain.

Over three years of in-clinic testing showed that this breakthrough all-natural program relieved significant chronic pain in 8 out of 10 people and with sustainable results. This non-narcotic, combination treatment has been receiving accolades from chronic pain sufferers with major improvement in mood and energy and dramatic decreases in pain levels, allowing a return to normal life function.

Innolife Pharma Inc. has an aggressive growth plan in place with a projected target of 95 licensed clinics in 3 years with projected top line annual revenue in excess of $30 million and a projected bottom line profit of over $12 million annually (40+%).

With the aging demographic, chronic pain is becoming a larger and larger international epidemic. Innolife Pharma Inc. is positioned to be the leading service provider in this segment - with a business model that is designed to provide excellent operating margins and tremendous growth for many years to come.

About Innolife Pharma Inc.

Innolife Pharma Inc. (PINKSHEETS: INNP) is a small publicly traded specialty multi-discipline medical group focusing on licensing the Natural Pain Relief Center all-natural proprietary breakthrough in the treatment of chronic pain.

FORWARD-LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE Innolife Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from ... performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, and ... important patterns in student test score performance, the report’s limited analyses fail to ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... contracted partners to help with process innovation in drug formulation and manufacturing. ... along with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine ... focus on preventative care with all my patients to alleviate possible future issues. I am ... to contact my office and my trained staff will assist you in any way possible.” ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology: